CAR-T

rainbow kite flying in the sky
Biotech

Kite sails into in vivo CAR-T space via $350M Interius buyout

Gilead has become the latest pharma to strengthen its in vivo credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics.
James Waldron Aug 21, 2025 9:59am
Monoclonal antibody orange red background 3d rendering

Allogene reports patient death tied to mAb in CAR-T pivotal trial

Aug 1, 2025 8:30am
Clear out clearnance rubbish scrap heap

AstraZeneca drops lead TCR therapy from $200M Neogene buy

Jul 29, 2025 4:13am
spray painting

BMS-backed Dispatch unveils with $216M, Carl June as cofounder

Jul 23, 2025 6:30am
Horseshoe magnet attracting metallic pawn people

Biotech shares first data for in vivo CAR-T that attracted AZ

Jul 7, 2025 2:27pm
End of road sign on street

Oncternal sells cancer assets to mystery biotech, winds down ops

Jul 1, 2025 9:38am